26-year old male dies from myocarditis less than 2 weeks after his first doze

A New Zealand man has died on November 17, 2021, after the Pfizer Covid-19 vaccine 'probably' caused a rare heart problem, authorities have revealed. This happened less than two weeks after taking his first dose on November 5. 

A preliminary postmortem examination identified myocarditis, a rare inflammation of the heart muscle, as the likely cause of death and New Zealand's Covid-19 Vaccine Independent Safety Monitoring Board said the issue was 'probably' brought on by the jab.

He started feeling 'flutters' a few hours after having his first dose of the vaccine but dismissed the symptoms as stress-related because he was in the process of selling and buying a house as well as planning a wedding.

Around 3am on November 17, the couple decided to go to hospital for 'reassurance' but he collapsed while getting ready to go in the bathroom and was later pronounced dead.   

The death is only New Zealand's second linked to a known but rare side effect from the vaccine after health authorities in August reported a woman had died after taking her doses. 


REFERENCES

Third death considered linked to COVID-19 vaccine | Ministry of Health NZ

New Zealand man, 26, died after Pfizer Covid vaccine 'probably' caused rare heart problem | Daily Mail Online

Dunedin man's death linked to vaccine | Otago Daily Times Online News (odt.co.nz)

'His death was so needless': Rory Nairn not warned of vaccine's myocarditis risk, inquest hears - NZ Herald

Pfizer: NZ coroner investigates Rory Nairn’s death after Covid-19 vaccine | Herald Sun

Coroner Confirms Pfizer Vaccine Caused New Zealand Man’s Death • Children's Health Defense (childrenshealthdefense.org)

Rory Nairn inquest: 'Death has not been forgotten' - NZ Herald

Coroner confirms Rory Nairn's death was due to Covid-19 vaccine | Stuff.co.nz


Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

Navigating the Tripledemic: JN.1, RSV, and Flu Update

Image
The respiratory viruses are out there.  Wastewater viral activity levels for COVID-19 , as reported by the Centers for Disease Control and Prevention, have reached the highest point since the Omicron surge in 2022. The levels are also high in Canada . The three primary respiratory illnesses continue to circulate at very high levels. But despite the triple threat of  SARS-Cov-2, respiratory syncytial virus ( RSV ) and the flu , there is a notable lack of community attention.   JN.1 (Pirola,  BA.2.86 ,  with additional L455S mutation, descending from a  de-escalated  variant of concern BA.2), initially detected on August 25 2023, has evolved from a variant under monitoring to a  variant of interest. Variants like Acrux (XBB.2.3, that began to spread worldwide soon after WHO declared the end of the pandemic) are  no longer relevant , but a few now less prevalent variants such as  Centaurus  (BA.2.75) and XBB, a hybrid of Centaurus with BA.2 lineage, that  gave rise to  Eris , its descend
Read more

The offshoots of JN.1 in the Evolutionary Trajectory of COVID-19

Image
While the current SARS-COV-2 viral activity levels may seem reassuring ( back to the levels seen in October-November 2023 ), the evolving world of JN.1 offshoots, where the next generation of variants is taking shape, presents a compelling case for anticipating the potential challenges that lie ahead.  From the widespread presence of JN.1.16 across continents to the emerging dominance of JN.1.13 in the U.S., the current variant landscape is rapidly shifting, although the potential implications for the future are not quite clear.  The roots of the pandemic can be traced back to lineage A, with many initial sequences originating from China and subsequently spreading globally, including to regions such as South East Asia, Japan, South Korea, Australia, the USA, and Europe. Lineage B followed as the second major haplotype, with subsequent evolutions leading to the emergence of various sublineages. In 2020, we witnessed the emergence of variants such as Alpha (B.1.1.7) and Delta (B.1.617.2
Read more